Lack of a Clinically Significant Pharmacokinetic Interaction between Fenofibrate and Pravastatin in Healthy Volunteers
- 8 March 2000
- journal article
- clinical trial
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 40 (3) , 316-323
- https://doi.org/10.1177/00912700022008874
Abstract
This study was conducted to evaluate the potential pharmacokinetic interaction between fenofibrate and pravastatin. A total of 23 healthy adult volunteers received single‐dose 201 mg fenofibrate alone, 201 mg fenofibrate + 40 mg pravastatin, and 40 mg pravastatin alone in a three‐period crossover experiment. Plasma samples were collected at predetermined times and were analyzed with validated methods for the quantitation of fenofibric acid, pravastatin, and 3α‐hydroxy‐iso‐pravastatin (3α‐iso‐PV). Pharmacokinetic parameters of these three compounds were calculated using noncompartmental methods and compared by analyses of variance and bioavailability assessments. Concomitant administration of fenofibrate and pravastatin did not affect the pharmacokinetics of either fenofibric acid or pravastatin. However, the AUC0‐∞ and Cmax of 3α‐iso‐PV were increased by 26% and 29%, respectively. The moderate increase in the formation of this pravastatin metabolite should not raise any clinical concerns due to its much lower pharmacological potency compared to pravastatin and lack of toxicity.Keywords
This publication has 15 references indexed in Scilit:
- Role of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors (“Statins”) in Familial Combined HyperlipidemiaThe American Journal of Cardiology, 1998
- Micronised FenofibrateDrugs, 1997
- Pharmacodynamics and Pharmacokinetics of the HMG-CoA Reductase InhibitorsClinical Pharmacokinetics, 1997
- Clinical Pharmacokinetics of 3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase InhibitorsClinical Pharmacokinetics, 1996
- Clinical Pharmacokinetics of PravastatinClinical Pharmacokinetics, 1994
- Pravastatin lowers serum cholesterol, cholesterol-precursor sterols, fecal steroids, and cholesterol absorption in manMetabolism, 1992
- Relative Lipophilicities, Solubilities, and Structure–Pharmacological Considerations of 3-Hydroxy-3-Methylglutaryl-Coenzyme A (HMG-CoA) Reductase Inhibitors Pravastatin, Lovastatin, Mevastatin, and SimvastatinJournal of Pharmaceutical Sciences, 1991
- Influence of Pravastatin, a Specific Inhibitor of HMG-CoA Reductase, on Hepatic Metabolism of CholesterolNew England Journal of Medicine, 1990
- Disposition of pravastatin sodium, a tissue‐selective HMG‐CoA reductase inhibitor, in healthy subjects.British Journal of Clinical Pharmacology, 1990
- HMG-CoA Reductase Inhibitors for Treatment of HypercholesterolemiaNew England Journal of Medicine, 1988